ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 176 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q3 2016. The put-call ratio across all filers is 0.44 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $1,381,463 | -50.8% | 12,133 | -66.2% | 0.01% | -63.6% |
| Q2 2020 | $2,809,000 | +202.7% | 35,910 | +71.9% | 0.03% | +230.0% |
| Q1 2020 | $928,000 | -33.3% | 20,889 | -35.9% | 0.01% | -9.1% |
| Q4 2019 | $1,391,000 | -9.3% | 32,568 | +50.8% | 0.01% | +57.1% |
| Q3 2016 | $1,533,000 | +1.7% | 21,600 | -29.9% | 0.01% | 0.0% |
| Q2 2016 | $1,507,000 | -11.2% | 30,800 | +14.9% | 0.01% | -30.0% |
| Q1 2016 | $1,697,000 | -80.5% | 26,800 | -70.4% | 0.01% | -80.0% |
| Q3 2015 | $8,710,000 | – | 90,430 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Abingworth LLP | 38,100 | $2,928,000 | 1.67% |
| Opaleye Management Inc. | 80,000 | $6,149,000 | 1.59% |
| HIGHLINE CAPITAL MANAGEMENT, L.P. | 410,000 | $31,517,000 | 1.06% |
| Opus Point Partners Management, LLC | 6,311 | $485,000 | 1.05% |
| SECTOR GAMMA AS | 68,015 | $5,228,000 | 0.87% |
| Capital Impact Advisors, LLC | 27,074 | $2,061,000 | 0.76% |
| FORTALEZA ASSET MANAGEMENT INC/ | 1,130 | $87,000 | 0.71% |
| CAPITAL INTERNATIONAL LTD /CA/ | 46,957 | $3,610,000 | 0.63% |
| Virtus ETF Advisers LLC | 8,794 | $676,000 | 0.60% |
| Rock Springs Capital Management LP | 200,000 | $15,374,000 | 0.59% |